Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. Clinical decision support systems (CDSSs) might be beneficial for the assessment of disease control. CDSSs should be based on the best evidence and algorithms to aid patients and health care professionals to jointly determine treatment and its step-up or step-down strategy depending on AR control. Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases for active and healthy ageing]), one of the reference sites of the European Innovation Partnership on Active and Healthy Ageing, has initiated an allergy sentinel network (the MACVIA-ARIA Sentinel Network). A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials.

Original publication

DOI

10.1016/j.jaci.2016.03.025

Type

Journal article

Journal

J Allergy Clin Immunol

Publication Date

08/2016

Volume

138

Pages

367 - 374.e2

Keywords

Allergic Rhinitis and its Impact on Asthma, Allergic rhinitis, MACVIA-LR, clinical decision support system, conjunctivitis, information and communication technology, Adolescent, Adult, Age Factors, Algorithms, Clinical Decision-Making, Conjunctivitis, Allergic, Disease Management, Humans, Patient Satisfaction, Rhinitis, Allergic